Latest Intelligence on Pharmaceutical Manufacturers in Asia-Pacific

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Daiichi Sankyo: pipeline filling at the O-KAI Corral

Daiichi Sankyo has signed a deal worth up to $340 million with KAI Pharmaceuticals for the global development and commercialization of KAI-9803, an experimental treatment for the prevention of myocardial tissue death. While this could represent an astute move by Daiichi to boost its cardio business, it could also be seen as a desperate pipeline-filling attempt following CS-505's recent failure.

Published By Datamonitor
11 Jan 2006
Expert View
Expert View

China: hepatitis treatment fails to keep pace with economy

According to a statement recently made by a senior health official in China, improvements in disease management and prevention have helped to transform infectious disease healthcare in China. However, there is still a considerable distance to go before China's healthcare system reaches western standards.

Published By Datamonitor
07 Feb 2006
CommentWire
CommentWire

Novo Nordisk/G2 Therapies: expanding operations

Novo Nordisk has signed a $100 million deal with Australian biotech firm G2 Therapies to develop a disease-modifying anti-rheumatic drug (DMARD). While the alliance should boost the fortunes of the relatively small biotech company and could aid Novo Nordisk in the potentially lucrative inflammation drugs market, a number of challenges lie ahead due to the nature of this market.

Published By Datamonitor
10 Feb 2006
Expert View
Expert View

Governmental cost-cutting helps generate generics growth

The generic cancer market was worth $1.3 billion in 2004 and is expected to reach $10.9 billion by 2014. This staggering level of growth is attributable to upcoming patent expiries on key products, as well as the imminent introduction of a biogenerics regulatory pathway. However, increasingly cost-conscious governments working to cut healthcare spending will remain generics firms' greatest ally.

Published By Datamonitor
06 Mar 2006
Expert View
Expert View

New advertising code of conduct established in Vioxx withdrawal fallout

Recent high-profile drug withdrawals have resulted in a new code of conduct to govern direct-to-consumer advertising. As more and more drugs are likely to come under regulatory and public scrutiny, the pharmaceutical industry will need to employ effective marketing and education strategies to ensure patient and physician confidence is retained and the impact of drug safety scares is minimized.

Published By Datamonitor
09 Mar 2006
Expert View
Expert View

Drug reps must embrace technology to avoid missing sales opportunities

In a pharmaceutical market where the days of the primary care blockbuster-selling drug appear numbered, the days of pharma sales representatives having time to visit physicians with drug samples are also waning. Reps must now embrace internet technology to ensure samples are efficiently distributed to physicians and also take on the role of educators in their dynamic relationships with physicians.

Published By Datamonitor
15 Mar 2006
ResearchWire
ResearchWire

Pulmonary arterial hypertension: market on the pulse of global growth

Published By Datamonitor
17 Mar 2006
ResearchWire
ResearchWire

Vaccines: sales show global growth

Published By Datamonitor
17 Mar 2006
ResearchWire
ResearchWire

Antihypertensives: ARBs at the heart of the market

Published By Datamonitor
27 Mar 2006
ResearchWire
ResearchWire

Cystic fibrosis: enzymes and antibiotics dominate the pipeline

Published By Datamonitor
30 Mar 2006

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.